Skip to main content
ALLIANCE PHARMA PLC logo

ALLIANCE PHARMA PLC — Investor Relations & Filings

Ticker · APH ISIN · GB0031030819 LEI · 213800RYIWZA4Q5WPZ13 IL Wholesale and retail trade
Open in API
Filings indexed 492 across all filing types
Latest filing 2015-11-26 Regulatory Filings
Country GB United Kingdom
Listing IL APH

About ALLIANCE PHARMA PLC

https://www.alliancepharmaceuticals.com/

Alliance Pharma PLC is an international specialty pharmaceutical company with a primary focus on consumer healthcare. The company's business model is centered on the acquisition, licensing, and marketing of a portfolio of consumer health products and prescription medicines. It operates globally, investing in its key brands to empower consumers to improve their health and wellbeing. A core part of its strategy is the ongoing development to become a high-performing consumer healthcare company.

Recent filings

Filing Released Lang Actions
Interim Dividend Timetable
Regulatory Filings Classification · 98% confidence The document is a short announcement (2297 characters) released via RNS (RNS Number : 1244H) from Alliance Pharma PLC on November 26, 2015. The core content announces a revision to the record date for the Interim Dividend, linking this change to a proposed acquisition. Since the document is an official notification regarding a change to a previously announced dividend schedule, it directly corresponds to the 'Notice of Dividend Amount' definition, even though it's a revision rather than the initial declaration. The presence of 'Interim Dividend Timetable - Revised Record Date' strongly points to the DIV code. It is not a full report (10-K, IR) nor a general announcement (RNS), but a specific dividend action.
2015-11-26 English
Proposed Acquisition
Regulatory Filings Classification · 98% confidence The document is an RNS announcement dated November 26, 2015, detailing a 'Proposed Acquisition of the Healthcare Products Business from Sinclair IS Pharma plc'. It explicitly mentions that the transaction constitutes a reverse takeover under the AIM Rules, requiring shareholder approval sought at a General Meeting. Crucially, it states: 'A combined Admission Document and Circular is being sent to the Company's shareholders today and will be available on the Investor Relations section of the Company's website'. This structure—announcing a major corporate action (acquisition, placing, and associated shareholder vote) and referencing the simultaneous publication of the formal Admission Document/Circular—is characteristic of a significant regulatory disclosure that mandates shareholder information and voting solicitation. Since the document itself is the announcement of the transaction and the associated shareholder meeting/document publication, it strongly aligns with the purpose of a Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders regarding meetings and related proposals. While it is a regulatory filing (RNS), PSI is more specific for documents related to seeking shareholder approval for major transactions like this acquisition and placing. The mention of the General Meeting and the need for shareholder approval points directly to PSI, which often accompanies or precedes the formal AGM/EGM materials.
2015-11-26 English
Directorate Change
Board/Management Information Classification · 99% confidence The document is a formal announcement released via RNS (RNS Number: 6702G) dated November 23, 2015. The core content explicitly states 'Directorate Change' and details that Anthony Booley is leaving the company and Peter Butterfield will assume his responsibilities. This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in senior management.
2015-11-23 English
Settlement Agreement
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated 05 November 2015. It announces a specific corporate event: a 'Settlement Agreement' with Sanofi Pasteur regarding compensation (£6.7m) related to a product (ImmuCyst™). This is a specific, material corporate announcement released via the London Stock Exchange's news service (RNS). It is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Since it is a specific, non-standard announcement that fits the description of general regulatory news released through the RNS system, the most appropriate classification is Regulatory Filings (RNS). It is too specific for the fallback 'RNS' category, but given the options, RNS is the best fit for a general regulatory news wire announcement that isn't covered by the other specific codes like DIRS, DIV, or CAP. However, upon re-evaluation against the definitions, this announcement details a significant financial settlement and use of proceeds (reducing debt), which could potentially fit under Capital/Financing Update (CAP) if the settlement was viewed as a financing event, or Legal Proceedings Report (LTR) as it settles a claim. Given the primary nature is a corporate announcement disseminated via RNS, and it doesn't fit perfectly into the other specific financial/legal categories, RNS remains a strong candidate. Since it is a specific corporate action announcement released via the RNS system, and it doesn't clearly map to LTR (legal proceedings update) or CAP (financing update), RNS serves as the appropriate general regulatory announcement category.
2015-11-05 English
Interim Dividend Timetable - Record Date
Notice of Dividend Amount Classification · 98% confidence The document is a short announcement (1990 characters) released via RNS (RNS Number: 6072Y) from Alliance Pharma PLC. The primary purpose of the text is to clarify and correct a previously announced detail regarding the record date for the interim dividend (changing it from 21 December 2015 to 18 December 2015). This is a specific announcement about a dividend detail, not the full dividend declaration itself, nor is it a general regulatory filing. Based on the definitions, the most specific category is 'Notice of Dividend Amount' (DIV), as it directly concerns the dividend timetable and record date. Although it is short and uses RNS, the content is highly specific to dividends, making DIV a better fit than the general RNS fallback.
2015-09-10 English
Interim Results
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Results for the six months ended 30 June 2015' and contains detailed financial statements, performance highlights, management commentary, and operational updates for Alliance Pharma PLC. It is a comprehensive report covering a period shorter than a full fiscal year, which fits the definition of an Interim/Quarterly Report (IR). It is not a mere announcement (RPA) as it contains substantive financial data and analysis. H1 2015
2015-09-09 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.